Compare WTI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTI | FHTX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.5M | 360.8M |
| IPO Year | 2005 | 2020 |
| Metric | WTI | FHTX |
|---|---|---|
| Price | $2.40 | $5.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.43 |
| AVG Volume (30 Days) | ★ 2.3M | 206.7K |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,094,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $40.91 |
| Revenue Next Year | $0.07 | $11.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $2.95 |
| 52 Week High | $2.59 | $6.95 |
| Indicator | WTI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 47.69 |
| Support Level | $2.04 | $5.18 |
| Resistance Level | $2.27 | $5.79 |
| Average True Range (ATR) | 0.11 | 0.34 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 77.23 | 27.15 |
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.